At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1,147 enrolled
Drug / intervention
AZD5069 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase II Study With an Optional Safety Extension Treatment Period up to 6 Months, to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting β2 Agonists (LABA), in Patients With Uncontrolled Persistent Asthma
In Brief
A Phase 2 clinical trial evaluating AZD5069 and Placebo for Asthma. Completed, enrolled 1,147 participants across 96 sites in 13 countries.
Detailed Summary
The purpose is to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting β2 Agonists (LABA), in Patients with Uncontrolled Persistent Asthma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesBulgaria, Canada, Czechia, Germany, Hungary, Mexico, Poland, Romania, Russia, Slovakia, South Africa, Ukraine, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 2012
Enrollment StartNov 2012
Primary CompletionAug 2014
TodayJul 2026
First PostedOct 11, 2012
Enrollment StartNov 1, 2012
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.7 years ago
Interventions
AZD5069drug
AZD5069 oral capsules self-administered twice daily.
Placebodrug
Placebo oral capsules self-administered twice daily.